Olopatadine HCL 0.1% Ophthalmic Solution
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) Troop Support has awarded contract SPE2D2-23-D-0007 for Olopatadine HCL 0.1% Ophthalmic Solution (5ML bottles). This contract, initially valued at an estimated $17.6 million over five years, has recently exercised Option Year 3, extending the period of performance through February 14, 2027. The award emphasizes small business participation.
Contract Details
- Contract Number: SPE2D2-23-D-0007
- Award Date: February 15, 2023
- Total Estimated Value: $17,621,453.20 (for Base Year + 4 Option Years)
- Period of Performance: Base Year + 4 Option Years. Option Year 3 is now active, covering February 15, 2026, through February 14, 2027.
- Contract Type: Indefinite-Delivery/Indefinite-Quantity (IDIQ)
- Set-Aside: The original solicitation focused on small business participation, including HUBZone, Service-Disabled Veteran-Owned Small Business, and Women-Owned Small Business concerns.
Scope of Award
This contract is for the procurement of Olopatadine HCL 0.1% Ophthalmic Solution in 5ML bottles, a critical drug product. The manufacturing and packaging are performed by Apotex Inc. in Richmond Hill, Ontario, Canada.
Key Modifications
The contract has undergone several modifications, with the most recent updates including:
- P00008 (Jan 27, 2026): Exercised Option Year 3, extending the contract through February 14, 2027.
- P00007 (Jan 27, 2026): Updated various FAR clauses, deleting provisions related to segregated facilities, EEO, and environmental management, and revising clauses on waste reduction and sustainable products. Contractors must review these changes for compliance.
- P00005 (Jan 21, 2025): Incorporated FAR 52.204-30, "Federal Acquisition Supply Chain Security Act Orders-Prohibition," requiring compliance with supply chain security measures.
- P00006 (Jan 21, 2025): Exercised Option Year 2, covering February 15, 2025, through February 14, 2026.
- P00004 (Jan 26, 2024): Exercised Option Year 1, covering February 15, 2024, through February 14, 2025.
- P00003 (Aug 24, 2023): Added Drug Supply Chain Security Act (DSCSA) compliance requirements to labeling.
- P00002 (Aug 24, 2023): Incorporated FAR 52.204-27, prohibiting the use of ByteDance covered applications (e.g., TikTok) on contract-related IT.
Contact Information
For inquiries, contact Kyle Lewicki (kyle.lewicki@dla.mil) or Jason Wray (Jason.wray@dla.mil) at DLA Troop Support.